PharmaCyte Biotech, Inc. (PMCB)

NASDAQ: PMCB · Real-Time Price · USD
1.720
-0.130 (-7.03%)
Nov 20, 2024, 4:00 PM EST - Market closed
-7.03%
Market Cap 13.21M
Revenue (ttm) n/a
Net Income (ttm) 4.50M
Shares Out 7.68M
EPS (ttm) 0.54
PE Ratio 3.21
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,677
Open 1.810
Previous Close 1.850
Day's Range 1.700 - 1.865
52-Week Range 1.390 - 2.580
Beta -0.20
Analysts n/a
Price Target n/a
Earnings Date Dec 13, 2024

About PMCB

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 2
Stock Exchange NASDAQ
Ticker Symbol PMCB
Full Company Profile

Financial Performance

Financial Statements

News

MyMD Pharmaceuticals Secures Strategic Investments

BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-r...

6 months ago - Business Wire

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (Nasdaq:MYMD) (“MyMD”) a clin...

6 months ago - Business Wire

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a biomedic...

Other symbols: FEMY
1 year ago - Business Wire

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in de...

1 year ago - Business Wire

PharmaCyte Biotech Announces Final Results of Tender Offer

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces the final results of its previously announced tender offer to acquire up to 7,750,00...

1 year ago - Business Wire

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicab...

1 year ago - Business Wire

PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Ce...

1 year ago - Business Wire

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

Topics to Include Continued Analysis of FDA's Clinical Hold on IND for Cell-in-a-Box® Topics to Include Continued Analysis of FDA's Clinical Hold on IND for Cell-in-a-Box®

2 years ago - GlobeNewsWire

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte and Iroquois have reached a settlement which includes appointing five new independent directors to PharmaCyte's reconstituted Board.

2 years ago - Business Wire

PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature li...

2 years ago - Business Wire

Iroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.

Reiterates its Belief that the Root Cause of the Company's Problems is an Insular and Dysfunctional Board Comprised of Chairman and CEO Kenneth Waggoner's Entrenched Management Team and Unqualified, H...

2 years ago - PRNewsWire

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature li...

2 years ago - Business Wire

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature li...

2 years ago - Business Wire

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

LAS VEGAS--(BUSINESS WIRE)--Preliminary Financial Results for Fiscal Year 2022 are announced by PharmaCyte Biotech, Inc.

2 years ago - Business Wire

IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS

NEW YORK , July 11, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), announced that on Friday, July 8, 2022, that it had delivered a written consent to...

2 years ago - PRNewsWire

IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS

NEW YORK , July 5, 2022 /PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc. ("PharmaCyte", "PMCB" o...

2 years ago - PRNewsWire

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature liv...

2 years ago - Business Wire

IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING

Believes Truly Independent Board Required to Increase Accountability Given PharmaCyte's Long History of Missed Milestones Highlights Severe Governance Deficiencies and Recent Half-Baked Efforts to App...

2 years ago - PRNewsWire

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its ...

2 years ago - Business Wire

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its ...

2 years ago - Business Wire

IROQUOIS CAPITAL DELIVERS OPEN LETTER TO PHARMACYTE BIOTECH BOARD OF DIRECTORS

Believes the Company's Recently Announced Initiatives are a Reactionary and Transparent Attempt to Placate Stockholders by Conveniently Implementing a Few of Iroquois' Long-Standing Recommendations Wi...

2 years ago - PRNewsWire

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its...

2 years ago - Business Wire

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte has authorized a share repurchase program to repurchase up to $10 million of PharmaCyte's outstanding common stock.

2 years ago - Business Wire

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

LAS VEGAS--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signa...

2 years ago - Business Wire

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

Expresses Disappointment in the Board's Failure to Articulate a Plan to Maximize Shareholder Value Amid Prolonged Product Development Efforts Despite the Company's Strong Cash Position Criticizes the ...

2 years ago - PRNewsWire